Leave nothing behind: Promising results for coronary drug-coated balloons in clinical practice.
Bimmer E P M ClaessenGeorge D DangasPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2019)
1,025 patients with de novo coronary artery disease (66.9%) or in-stent restenosis (ISR) (33.1%) underwent treatment with paclitaxel drug-coated balloons in a multinational single-arm registry. Bail-out stenting rate was only 4.8%. One-year target lesion revascularization was 2.3% for de novo lesions, 2.9% for bare metal stent ISR, and 5.8% for drug-eluting stent ISR. Short-term results with coronary drug-coated balloons are promising. Nonetheless, long-term data, preferably from randomized trials are necessary to confirm their safety and efficacy.
Keyphrases
- coronary artery disease
- percutaneous coronary intervention
- coronary artery
- clinical practice
- coronary artery bypass grafting
- cardiovascular events
- adverse drug
- drug induced
- antiplatelet therapy
- cardiovascular disease
- acute coronary syndrome
- heart failure
- big data
- machine learning
- aortic stenosis
- left ventricular
- transcatheter aortic valve replacement
- combination therapy
- aortic valve